Immediate Impact of Artificial Tear Composition on Optical Aberrations: A Comparative Study of Lipid and Non-Lipid Hydroxypropyl Guar Formulations.

IF 3.2 3区医学 Q2 OPHTHALMOLOGY

Ophthalmology and Therapy Pub Date : 2025-07-17 DOI:10.1007/s40123-025-01205-z

José-María Sánchez-González, María Carmen Sánchez-González, Concepción De-Hita-Cantalejo, Henrique Nascimento, Clara Martinez-Perez

{"title":"Immediate Impact of Artificial Tear Composition on Optical Aberrations: A Comparative Study of Lipid and Non-Lipid Hydroxypropyl Guar Formulations.","authors":"José-María Sánchez-González, María Carmen Sánchez-González, Concepción De-Hita-Cantalejo, Henrique Nascimento, Clara Martinez-Perez","doi":"10.1007/s40123-025-01205-z","DOIUrl":null,"url":null,"abstract":"Introduction: To evaluate the immediate effects of two artificial tear formulations-mineral oil + hydroxypropyl guar (HP-Guar) and hyaluronic acid (HA) + HP-Guar-on ocular aberrations in healthy participants.Methods: A randomized, participant-masked clinical trial was conducted on 98 right eyes of 98 participants (mean age: 27.96 ± 10.00 years). Participants received a single instillation of either a lipid-based (mineral oil + HP-Guar) or non-lipid (HA + HP-Guar) artificial tear solution. Ocular aberrations were measured before and 10 min post-instillation using a wavefront aberrometer (i.Profilerplus®, Carl Zeiss Meditec, Jena, Germany) at pupil diameters of 3 mm and 5 mm. Root mean square (RMS) values for total, low-order, and high-order aberrations were analyzed.Results: The mineral oil + HP-Guar formulation significantly reduced total RMS (p < 0.05) and low-order RMS (p < 0.05) at both 3-mm and 5-mm pupil diameters. Notable reductions were observed in defocus (Z20), vertical astigmatism (Z22), and trefoil (Z3-3). Both formulations significantly increased high-order RMS (p < 0.05).Conclusions: Lipid-based artificial tears provide superior optical quality by reducing total and low-order ocular aberrations, making them preferable for patients with tear film instability. In contrast, HA-based formulations primarily improve hydration with limited impact on optical performance. Artificial tear selection should consider both symptomatic relief and refractive stability, especially for individuals with high visual demands.Clinical trial registration: This study was registered as a randomized clinical trial on ClinicalTrials.gov under the identifier NCT06784661, titled the ILEACT study.","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40123-025-01205-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: To evaluate the immediate effects of two artificial tear formulations-mineral oil + hydroxypropyl guar (HP-Guar) and hyaluronic acid (HA) + HP-Guar-on ocular aberrations in healthy participants.

Methods: A randomized, participant-masked clinical trial was conducted on 98 right eyes of 98 participants (mean age: 27.96 ± 10.00 years). Participants received a single instillation of either a lipid-based (mineral oil + HP-Guar) or non-lipid (HA + HP-Guar) artificial tear solution. Ocular aberrations were measured before and 10 min post-instillation using a wavefront aberrometer (i.Profilerplus^®, Carl Zeiss Meditec, Jena, Germany) at pupil diameters of 3 mm and 5 mm. Root mean square (RMS) values for total, low-order, and high-order aberrations were analyzed.

Results: The mineral oil + HP-Guar formulation significantly reduced total RMS (p < 0.05) and low-order RMS (p < 0.05) at both 3-mm and 5-mm pupil diameters. Notable reductions were observed in defocus (Z₂⁰), vertical astigmatism (Z₂²), and trefoil (Z₃^-3). Both formulations significantly increased high-order RMS (p < 0.05).

Conclusions: Lipid-based artificial tears provide superior optical quality by reducing total and low-order ocular aberrations, making them preferable for patients with tear film instability. In contrast, HA-based formulations primarily improve hydration with limited impact on optical performance. Artificial tear selection should consider both symptomatic relief and refractive stability, especially for individuals with high visual demands.

Clinical trial registration: This study was registered as a randomized clinical trial on ClinicalTrials.gov under the identifier NCT06784661, titled the ILEACT study.

查看原文本刊更多论文

人工泪液成分对光学像差的直接影响：脂质和非脂质羟丙基瓜尔胶配方的比较研究。

前言：评价矿物油+羟丙基瓜尔胶（HP-Guar）和透明质酸(HA) + hp -瓜尔胶两种人工泪液配方对健康受试者眼像差的直接影响。方法：对98例（平均年龄27.96±10.00岁）患者的98只右眼进行随机、受试者蒙面临床试验。参与者接受单次滴注脂类（矿物油+ hp -瓜尔胶）或非脂类（HA + hp -瓜尔胶）人工泪液。使用波前像差仪（i.p profilerplus®，卡尔蔡司Meditec，耶拿，德国）在瞳孔直径为3 mm和5 mm时测量注射前和注射后10 min的眼像差。对总、低阶和高阶像差的均方根（RMS）值进行分析。结果：矿物油+ hp -瓜尔胶制剂可显著降低总RMS （p 20）、垂直散光（Z22）和三叶草（Z3-3）。两种配方均显著提高了高阶RMS (p)。结论：脂质人工泪液通过降低总像差和低阶眼像差提供了优越的光学质量，使其更适合泪膜不稳定的患者。相比之下，ha基配方主要改善水合作用，对光学性能的影响有限。人工泪液的选择应考虑症状缓解和屈光稳定性，特别是对视力要求高的个体。临床试验注册：该研究在ClinicalTrials.gov上注册为随机临床试验，编号为NCT06784661，标题为ILEACT研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ophthalmology and Therapy OPHTHALMOLOGY-

CiteScore

4.20

自引率

3.00%

发文量

157

审稿时长

6 weeks

期刊介绍： Aims and Scope Ophthalmology and Therapy is an international, open access, peer-reviewed (single-blind), and rapid publication journal. The scope of the journal is broad and will consider all scientifically sound research from preclinical, clinical (all phases), observational, real-world, and health outcomes research around the use of ophthalmological therapies, devices, and surgical techniques. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/series, trial protocols and short communications such as commentaries and editorials. Ophthalmology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. Rapid Publication The journal’s publication timelines aim for a rapid peer review of 2 weeks. If an article is accepted it will be published 3–4 weeks from acceptance. The rapid timelines are achieved through the combination of a dedicated in-house editorial team, who manage article workflow, and an extensive Editorial and Advisory Board who assist with peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid, efficient communication of the latest research and reviews, fostering the advancement of ophthalmic therapies. Open Access All articles published by Ophthalmology and Therapy are open access. Personal Service The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning authors will always have an editorial contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that articles conform to the most recent COPE, GPP and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research. Digital Features and Plain Language Summaries Ophthalmology and Therapy offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by key summary points, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. If you consider that your paper would benefit from the inclusion of a digital feature, please let us know. Our editorial team are able to create high-quality slide decks and infographics in-house, and video abstracts through our partner Research Square, and would be happy to assist in any way we can. For further information about digital features, please contact the journal editor (see ‘Contact the Journal’ for email address), and see the ‘Guidelines for digital features and plain language summaries’ document under ‘Submission guidelines’. For examples of digital features please visit our showcase page https://springerhealthcare.com/expertise/publishing-digital-features/ Publication Fees Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of €5250/$6000/£4300. The journal will consider fee discounts and waivers for developing countries and this is decided on a case by case basis. Peer Review Process Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria. At least two extensive reviews are required to make the editorial decision, with the exception of some article types such as Commentaries, Editorials, and Letters which are generally reviewed by one member of the Editorial Board. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case-by-case basis and should be sent to the journal editor. Preprints We encourage posting of preprints of primary research manuscripts on preprint servers, authors’ or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Authors should disclose details of preprint posting during the submission process or at any other point during consideration in one of our journals. Once the manuscript is published, it is the author’s responsibility to ensure that the preprint record is updated with a publication reference, including the DOI and a URL link to the published version of the article on the journal website. Please follow the link for further information on preprint sharing: https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550 Copyright Ophthalmology and Therapy''s content is published open access under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0. Contact For more information about the journal, including pre-submission enquiries, please contact christopher.vautrinot@springer.com.